Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.09

+0.4%

12:49 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biomaven	5/21/2007 3:10:55 PM
	Read Replies (5) of 52153

I'm trying to think through the fallout from Avandia today. More questions than answers at this point. Is this a class effect or not? Who stands to benefit (other than trial lawyers) if this drug dies? AMLN? Who else is at risk if it is a class effect? If not, presumably Actos benefits. Thoughts and comments welcomed. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next